MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • January 2019

ROOT OF SKIN™ Skincare Line Sets Records in Fourth Consecutive Sell Out on QVC Japan

AIVITA Biomedical to Present at Upcoming January Healthcare Conferences

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

ROOT OF SKIN™ Skincare Line Sells Out Again During Third Appearance on QVC Japan

AIVITA Biomedical to Present at Biotech Showcase 2019

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead Leads Multidisciplinary Team of Scientists Invited by Dalai Lama to Discuss Consciousness
  • AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022
  • AIVITA Biomedical Announces Publication Detailing 50% Enhanced Survival in Phase 2 GBM Study
  • AIVITA Biomedical CEO Dr. Hans Keirstead Wins Innovator of the Year Award

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.